4.3.5 Targeted therapies and immunotherapy
The Therapeutic Goods Administration has recently provisionally approved targeted therapy for treating selected patients with advanced or recurrent endometrial cancer.
Endometrial cancer is a heterogenous disease and there is work being carried out to identify sub-groups that might impact future treatment selection.